• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real ‐world analysis
ConclusionIn obese patients with congestive heart failure and atrial fibrillation or atrial flutter on DOACs, apixaban has the most favorable safety profile compared to rivaroxaban and dabigatran.
Source: Pacing and Clinical Electrophysiology : PACE - December 2, 2022 Category: Cardiology Authors: Yashasvi Chugh, Kashvi Gupta, Hanumanthu Balram Krishna, Renato Quispe Ayala, Ignacio Zepeda, Michael Grushko, Robert T Faillace Tags: ORIGINAL ARTICLE Source Type: research

Safety and Efficacy of Rivaroxaban, Apixaban, and Dabigatran in Obese and Morbidly Obese Patients with Heart Failure and Atrial Fibrillation: A Real ‐World Analysis
ConclusionIn obese patients with congestive heart failure and atrial fibrillation or atrial flutter on DOACs, apixaban has the most favorable safety profile compared to rivaroxaban and dabigatran.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - November 24, 2022 Category: Cardiology Authors: Yashasvi Chugh, Kashvi Gupta, Hanumanthu Balram Krishna, Renato Quispe Ayala, Ignacio Zepeda, Michael Grushko, Robert T Faillace Tags: ORIGINAL ARTICLE Source Type: research